Hi Here is a news release but there should be more to follow. The shareholder's meeting is thursday that is my guess for more news. This stock is for real.....
Tuesday September 28, 6:59 am Eastern Time
Company Press Release
SOURCE: Biotech Holdings Ltd.
Biotech Signs Chile Licensing Agreement for Its
Diabetes Drug, DIAB II
VANCOUVER, British Columbia, Sept. 28 /PRNewswire/ -- Robert B. Rieveley,
President of Biotech Holdings Ltd. (``Biotech') (OTC Bulletin Board: BIOHF - news), is pleased to announce that Biotech has
signed a licensing agreement for the distribution of Biotech's Adult-Onset Diabetes drug, DIAB II, in Chile. Under the
agreement, Biotech has granted marketing and distribution rights for seven years to Laboratorios SAVAL.
``SAVAL,' Mr. Rieveley said, ``is one of the most dynamic pharmaceutical companies in Chile. SAVAL, with four hundred
employees, is third in sales in the Chilean pharmaceutical market and second in the number of prescriptions filled. SAVAL will
co-operate with Biotech in the preparation of a registration dossier for DIAB II in Chile. We believe that SAVAL will prove to
be a strong partner for bringing DIAB II to the Chilean market.'
In addition to the agreement for Chile, Biotech has licensing agreements for DIAB II in Brazil, Argentina, Venezuela and Peru
and is negotiating with pharmaceutical firms in a number of other Latin American markets. For North America and Western
Europe, Biotech's business plan is based on the Company's continuing discussions with a number of international
pharmaceutical companies to create a relationship that would lead to submitting DIAB II for approval to the US FDA.
DIAB II, an oral diabetes drug, is an insulin-receptor sensitizer. DIAB II belongs to a new class of drugs that is used to control
the chronically high blood sugar level that typifies diabetes. DIAB II works by improving the patient's ability to utilize both
endogenous and injected insulin, the hormone that controls blood sugar levels. Studies of the drug, including a clinical trial
recently concluded in Brazil, have shown it to be both effective and safe. Type II Diabetes affects more than 17 million people
in North America, over 20 million in Latin America and over 150 million worldwide.
Biotech Holdings Ltd. is based in Vancouver, British Columbia and has its laboratory and plant facility in Richmond, BC.
Biotech Holdings trades on the Over the Counter Bulletin Board in the United States (OTC BB symbol: BIOHF) and on the
Alberta Stock Exchange (ASE symbol: BIO). For inquiries, contact Austin Rand at Biotech Holdings Ltd. 1-888-216-1111
(toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail at biotech@direct.ca. Please visit Biotech's website at
biotechltd.com.
This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of
1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are
reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the
countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market
conditions. These forward-looking statements represent the Company's judgement at the date of this release and any changes in
assumptions or external factors could produce significantly different results.
SOURCE: Biotech Holdings Ltd. |
